Skip to main content

Medtronic plc guidance

  • MDT · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$103.13+0.24%Close 17 Nov 2026 · Market value $132.2B · Next results 24 Nov 2026

In its results release of 1 Sep 2026 (Q1 FY2027), Medtronic plc gave 1 forecast in figures, among them EPS (adjusted) of $5.94 to $6.00 for FY2027.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q1 FY2027 results, 1 Sep 2026

MeasurePeriodGuidanceAs stated
EPS · Adjusted · RaisedFY2027$5.94 to $6.00Raising FY27 organic revenue growth guidance 50 basis points to 7.25% to 7.75%, and FY27 diluted non-GAAP EPS guidance to the new range of $5.94 to $6.00

Source: the company's earnings release.

Guidance against results last two years

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
Organic revenue growthFY2027+6.75% to +7.25%Given once—To come
EPS · AdjustedFY2027$5.94 to $6.00Raised once—To come
EPS growth · AdjustedFY2027+6.7% to +8.5%Given once—To come
Revenue growthFY2026+6.5% to +6.8%Raised once+8.43%Above the range
Revenue growthFY2025+3.4% to +3.8%Lowered once+3.62%Within the range

MDT in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.